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Abstract 
Breast cancer is the most frequent cause of cancer of women in much of the world. In countries with screening 
programs, breast cancer is often detected before clinical symptoms are apparent, but occasionally the occurrence of a 
paraneoplastic syndrome precedes the identification of cancer. In breast cancer, there are known to be paraneoplas-
tic endocrine syndromes and neurologic syndromes. The neurologic syndromes are often hard to identify and treat. 
The neurologic syndromes associated with breast cancer include cerebellar degeneration, sensorimotor neuropathy, 
retinopathy, stiff-persons syndrome, encephalitis, and opsoclonus–myoclonus. Most of these are mediated by anti-
bodies against known neural antigens, although some cases appear to be mediated by non-humoral mechanisms. 
Treatments differ depending upon the syndrome type and etiology. Outcomes also vary depending upon duration 
of disease, the treatments used and the responsiveness of the underlying cancer. A thorough review of the published 
literature is provided along with recommendations for management and future research.
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Background
Breast cancer is the most common non-skin cancer in 
women in the United States with an estimated one in 
eight lifetime risk. Similarly high rates are observed in 
many other parts of the world. The incidence rate in the 
United States has remained stable for the last 15 years. 
Breast cancer death rates, however, decreased by 34  % 
since 1990 suggesting that progress is being made in 
breast cancer treatment and detection. Nevertheless, a 
cure for metastatic disease has not been achieved and 
some deficiencies in treatment of advanced disease per-
sist [1, 2]. One important deficiency in the field of breast 
cancer is a lack of robust data for the characterization, 
detection and management of paraneoplastic neurologic 
syndromes. Since paraneoplastic syndromes are rare 
in breast cancer, no prospective studies have been per-
formed. Paraneoplastic neurologic syndromes are often 
severely debilitating, hard to diagnose, and challenging to 
treat.
It is unknown whether certain patient subsets might 
be at greater risk for paraneoplastic syndromes in breast 
cancer. Receptor typing and histological subtype have lit-
tle known impact on the likelihood of developing parane-
oplastic syndromes. Other clinical factors such as lymph 
node involvement, lymphovascular space invasion and 
perineural invasion are known adverse factors for breast 
cancer in general, but it is unknown whether these fac-
tors confer increased risk for development of paraneo-
plastic syndromes. Finally, nodal status is related to rate 
and timing of metastatic disease normally [3], but has 
no relationship to timing of paraneoplastic syndromes. 
Those syndromes may develop at any point in the course 
of breast cancer, even preceding the formal diagnosis of 
breast cancer in some cases [4].
The diagnosis of a paraneoplastic syndrome is chal-
lenging due to heterogeneity in timing, symptomatol-
ogy and presence of onconeural antibodies. Antibodies 
are only found in 60–70  % of paraneoplastic syndrome 
patients with breast cancer. Therefore antibody testing 
may be helpful if positive, but the absence of antibodies 
cannot rule out a paraneoplastic neurologic syndrome. 
To address these issues, the international panel of neu-
rologists defined four components for the diagnosis of 
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paraneoplastic neurological disorders. These are, (1) the 
presence of neurological symptoms, (2) a diagnosis of 
cancer within 4 years from the onset of the neurological 
manifestations, (3) exclusion of other neurological dis-
orders and (4) at least one of the following: CSF analy-
sis showing inflammation with negative cytology, a brain 
MRI demonstrating a lesion in the temporal lobe, or the 
finding of epileptic activity in the temporal lobes by elec-
troencephalogram (EEG) [5–7].
It is well documented that breast cancer is immuno-
genic and several recent successes with checkpoint inhib-
itors and vaccines attest to this fact [8]. Indeed several 
unique and shared tumor antigens have been identified 
for each subtype of breast cancer. The TCGA studies have 
confirmed that mutations or loss of the p53 tumor sup-
pressor are common and may contribute to the cancer 
phenotype. By permitting unchecked cell division, these 
p53 defects likely are permissive to expression of mutated 
or mis-folded proteins that would otherwise not be “vis-
ible” to the immune system. Inherited and acquired 
defects in DNA repair (BRCA 1&2, PALB2, CHEK2, etc.) 
are also well known contributors to mutation in breast 
cancer. There are many other cellular events and mecha-
nisms which contribute to aberrant antigen expression in 
cancer (DNA methylation/acetylation changes, mRNA 
binding protein changes, exosomes, etc.) The ultimate 
result of several sub-cellular changes in the cancer cell 
and the stroma is that the immune system is frequently 
primed to recognize tumor-associated epitopes as for-
eign. The resulting aberrant antigen/neo-antigen expres-
sion, glycosylation, and changes in protein degradation 
occur in the setting of cancer cells that are undergoing 
rapid expansion which sets the stage for dendritic cells 
to scavenge cellular debris and carry “hidden” or oth-
erwise novel antigens to the draining lymph nodes and 
other lymphoid organs. In the nodes or lymphoid organs, 
amplification of the immune response may occur includ-
ing B and T lymphocyte selection and expansion [9–12]. 
Unfortunately not all the B and T lymphocyte responses 
produce anti-tumor effects. Some may be tolerogenic, 
some may be involved in memory response, and rarely 
some may result in responses against auto-antigens. 
Auto-recognition then leads to autoimmune and/or para-
neoplastic syndromes. Additional T cell and B-cell medi-
ated mechanisms of neuronal damage have been well 
described previously and are summarized in Fig. 1.
Paraneoplastic neurological syndromes have been 
reported in breast cancer as early as 1968. Those syn-
dromes can be quite debilitating when they occur. 
Currently, breast cancer related neurologic paraneo-
plastic syndromes include sensory and motor-type 
neuropathies, paraneoplastic cerebellar degeneration, 
opsiclonus–myoclonus syndrome, stiff person syndrome, 
enchephalomyelitis (including limbic encephalopathy) 
and paraneoplastic retinopathy.
The most compelling study of pathobiology was 
reported for 131 breast cancer patients in 2011. In that 
study, it was suggested that the tumor microenvironment 
and bone marrow resident T cells may play a role in the 
development of humoral paraneoplastic syndromes [13]. 
Specifically, T cell reactivity to autoantigens was tested 
by ELIspot assay. Patients with autoreactive T cells had 
intratumoral IFN-α concentrations above 10  pg/ml and 
patients with serum autoantibodies had significantly 
increased levels of intratumoral IL-12 compared to anti-
body negative patients (p =  0.04). Serum samples from 
breast cancer patients were examined for anti-nuclear 
antibodies (ANA), anti-neutrophil cytoplasmic anti-
bodies (ANCA), thyroid-stimulating hormone receptor 
antibodies (TRAb), rheumatoid factors (RhF), and anti-
thyreoglobulin antibodies (TgAb). ANAs were detected 
in 29/85 (34.1 %), ANCAs in 3/86 (3.5 %), TRAbs in 0/86 
(0 %), RhF in 4/85 (4.7 %), and TgAbs in 27/85 (31.8 %) 
patients analyzed. In total, 49 out of 86 patients (57  %) 
had at least one positive antibody result. The same group 
had previously detected reactivity against HLA-A*0201-
restricted tumor-associated antigens in 33 % of all breast 
cancer patients versus reactivity against normal breast 
tissue-associated antigens was seen in 24 % [14]. Further, 
IFN-α is increased in breast cancer patients with immune 
recognition of tumor. Since IFN-α amplifies T-cell auto-
reactivity by supporting T-cell activation and survival, it 
likely contributes to paraneoplastic syndromes. Likewise, 
IFN-α suppresses the generation of CD4+FoxP3HI regula-
tory T cells, thus weighing immune homeostasis toward 
autoimmunity [13, 14].
Paraneoplastic cerebellar degeneration
Paraneoplastic cerebellar degeneration (PCD) is fairly 
rare in general and is seen in less than 1  % of cancers. 
It has been associated with small cell carcinoma of the 
lung, Hodgkin’s lymphoma, breast cancer and gyneco-
logic malignancies. It presents clinically with moderate to 
severe truncal ataxia, nystagmus, vertigo, dysarthria and 
sometimes diplopia. The onset may be acute or subacute 
and by definition should be without the presence of brain 
metastases or direct CNS invasion [15].
The first case to be diagnosed with PCD was attrib-
uted to Brouwer whose patient suffered from “pleomor-
phic cell sarcoma of the pelvis”. Another case of PCD was 
reported in 1929 occurring 2 years after a mastectomy. A 
total of 62 cases of PCD were eventually identified and 
fully characterized between 1966 and 1990. Those 62 
patients tended to present with early stage cancers. Only 
three of them were described to have had metastatic dis-
ease at the time of the PCD diagnosis. Two additional 
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patients were described as having only regional nodal dis-
ease. Cerebrospinal fluid (CSF) analysis was performed 
and showed the presence of the anti-Yo antibody (previ-
ously termed anti-Purkinje antibody) in 19 patients. All 
19 patients with anti-Yo positivity in the CSF also had 
anti-Yo positivity in their sera. At autopsy, PCD patients 
show decreased cerebellar size, diffuse loss of Purkinje 
cells throughout the cerebellar cortex, and also a loss of 
granule and basket cells.
The clinical presentation of PCD is variable. Trunk 
and limb ataxia, dysarthria, diplopia and vertigo tend to 
predominate in the anti-Yo mediated cases while the fre-
quency of nystagmus and dysarthria is lower in patients 
mediated by anti-Ri (antineuronal nuclear antibody type 
2) or other antibodies discussed below. Psychiatric symp-
toms have also variably been reported. In anti-Hu asso-
ciated PCD, non-cerebellar symptoms and psychiatric 
symptoms were more frequent. It is estimated that 20 % 
of patients with PCD will develop cognitive disorders 
[16].
A clinical challenge for PCD diagnosis is that the cere-
bellum is radiographically normal in most of the reported 
cases of PCD and many patients may present well before 
a cancer diagnosis is known. Indeed, radiographic 
changes in cerebellar size are usually only seen in the late 
stages of the disease. Most of the time, PCD patients have 
associated onco-neural antibodies, most often anti-Yo 
or anti-Ri which can help confirm the diagnosis. In the 
rare antibody negative PCD cases, the neurologic dis-
ease appears to be rapidly progressive and unrelenting 
[17–19]. The neurologic manifestations of PCD often 
ante-date the diagnosis of breast cancer. Indeed, a case 
series observed neurologic manifestations of PCD before 
breast cancer diagnosis in 77 % of cases. The time range 
in that series was 2–41  months before cancer diagnosis 
[18].
A majority of PCD cases are mediated by anti-Yo anti-
bodies. In 1987 the target proteins of anti-Yo were found. 
The proteins are coded by the cerebellar degeneration 
related gene (CDR) which is expressed mainly in the 
Purkinje cells. There are two known isoforms, a minor 
34-kD antigen (CDR34) and a 64-kD antigen (CDR64) 
[20, 21]. Not surprisingly, the antibodies usually react 
against autologous tumor cells expressing these antigens 
(aberrantly). Antibody dependent cellular cytotoxicity 
has also been reported, but there remains some debate 
as to whether the anti-Yo is the primary mediator of the 
cellular damage or merely a bystander. To further com-
plicate the debate about the direct role of anti-Yo, it was 
found that anti-Yo may be found in healthy non-cancer 
patients and may be associated with attention deficit dis-
order. Thus, it remains unclear what role anti-Yo plays in 
cerebellar Purkinje cell loss [22].
Despite the debate about mechanism, the finding of 
anti-Yo in any patient with cerebellar disease should be a 
red flag to look for underlying malignancy. In one series, 
100  % of anti-Yo patients were diagnosed with malig-
nancy on further follow-up [23]. On the other hand, not 
all cases of PCD are associated with anti-Yo specifically. 
In a series of 50 patients with antibody associated PCD, 
19 patients had anti-Yo, 16 had anti-Hu, seven had anti-
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Fig. 1 Simplified mechanism of paraneoplastic immune neurologic injury. This figure summarizes the theorized immune mechanism of paraneo-
plastic neurologic syndromes. The beast tumor microenvironment contains immune cells such as CD4+ T cells, CD8+ T cells, NK cells, macrophages, 
dendritic cells (DC) and others. When tumor cells undergo apoptosis, the DC’s may phagocytose them, travel to lymphoid nodes (or other lymphoid 
structures) to present antigen to CD4+ and CD8+ T-cells and even B-cells. Certain activated T cells and autoimmune antibodies may then cross the 
blood brain barrier where normally immunologically privileged neurons may be targeted by antibody or T cells or both
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Ultimately all of patients that tested positive for anti-Yo, 
anti-Tr and anti-mGluR1, had a clinical syndrome con-
sistent with PCD. Another series of 92 patients with par-
aneoplastic neurologic syndromes associated with breast 
or gynecologic cancers found 63 patients with onconeu-
ral antibodies (50 anti-Yo, 5 anti-Hu, 5 anti-Ri, and 3 
anti-amphiphysin). Fifty-seven patients (62 %) developed 
cerebellar ataxia; 88 % of them were found to have anti-
Yo [24].
PCD has a poor prognosis and treatment options are 
limited. The use of intravenous immunoglobulin (IVIG), 
corticosteroids, plasmapheresis and cyclophosphamide, 
have all been tried individually or in combination, and 
they have low response rates. Because PCD has an auto-
immune mechanism of action, elimination of the antigen 
source may be helpful. Indeed, resection of the primary 
tumor is reported to reduce the neurological manifes-
tations of PCD [45, 46]. The median survival time in 
patients treated with anti-tumor therapy is longer than 
those not receiving anti-tumor therapy regardless of the 
use of immunotherapy (hazard ratio 0.3; 95 % confidence 
interval 0.1–0.6; p = 0.004) [47]. Despite a survival advan-
tage to treatment of the underlying cancer, the functional 
outcomes for PCD patients remain abysmal. In a series of 
55 women with breast and gynecologic cancer and anti-
Yo mediated PCD, the most common neurologic out-
come was severe disability. PCD was disabling in 37 of the 
patients to the degree that they were unable to walk or sit 
unsupported. These late disabling neurological manifesta-
tions generally did not respond to treatment [16].
The long-term outcome was further evaluated in a 
series of 34 women with PCD. Twelve of the patients had 
breast cancer. The PCD diagnosis preceded the diagnosis 
of primary tumor in 19 patients. Six patients were diag-
nosed with PCD after diagnosis and treatment were com-
plete. Overall, the cause of death was related to tumor 
progression in 12 patients and to PCD in 9 patients and 
unknown in two patients. The median survival time 
was 22  months in patients with ovarian cancer and 
100 months in patients with breast cancer. At the time of 
analysis, 13 out of the 18 patients with ovarian cancers 
were dead (72 %) and cancer progression was the cause 
of death in 61 %. By contrast only 5 out of the 12 patients 
with breast cancer were dead (42 %) [48, 49].
In terms of treatment for PCD, there is one patient 
series describing use of a combination of IVIG, cyclo-
phosphamide and methylprednisolone. The patients 
received one to nine cycles (mean 3.5) of that combi-
nation. There was no reported toxicity and the toler-
ance was satisfactory. Unfortunately, the best response 
to treatment was stable disease, which was observed in 
three out of seven patients [50]. Another descriptive 
report of 15 cases of antibody-mediated PCD analyzed 
the use of IVIG either alone or in combination with other 
therapies. It was concluded that the best responses were 
seen when IVIG treatment was begun within the first 
month of symptoms. Patients that received treatment 
between 1 and 3 months of symptom onset often had sta-
ble disease, while patients who received therapy beyond 
three months from onset had poorer outcomes. This 
Table 1 Summary of anti-neuronal antibodies in paraneoplastic neurologic diseases
Primary anti-neuronal antibody Other associated anti-neuronal antibodies


















Stiff person syndrome Anti-GAD and Anti-amphiphysin [34, 35]
Paraneoplastic sensory peripheral neuropathy Anti-Hu, Anti-Yo, Anti-Ri [36–38]
Paraneoplastic limbic encephalomyelitis Anti-Hu [39–44] Anti-Ta
Anti-Ma
[39–44]
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series was unable to compare between double and triple 
agent therapy. It was suggested that high doses of IVIG 
and steroids as early as possible in the course of PCD may 
be useful [51].
Retinopathy
Paraneoplastic retinopathy is a rare breast cancer com-
plication, which like other paraneoplastic syndromes is 
mediated by aberrant immune cross-recognition of anti-
gen. Affected patients experience photosensitivity, diffi-
culties in visual acuity, impaired color vision, peripheral 
scotomas or prolonged dark adaption. Paraneoplastic 
retinopathy is most associated with melanoma and small 
cell lung cancer but it has also been reported with breast 
cancer and less commonly with other cancers (Table  2) 
[52, 53]. Indeed in one academic retina clinic, breast can-
cer made up 31 % of cancer associated retinopathy cases 
[54]. Because the retina is immunologically privileged, 
the immune system is not normally exposed or toler-
ized to the retinal antigens and thus aberrant expression 
by cancer cells may result in B and T cell recognition of 
auto-antigens. It is known that abnormal expression of 
retinal proteins occurs in breast cancer cells and pre-
sumably that is the source for dendritic cell exposure 
to retinal antigen and the eventual B-cell production of 
autoantibody [55–58]. The production of anti-retinal 
antibodies is shown to cause direct damage to retinal 
enolase, rods, cones, and several other retinal structures 
[59–63].
As with paraneoplastic cerebellar degeneration previ-
ously discussed, there are occasional retinopathy cases 
for which antibody cannot be detected in serum. It 
remains unclear whether the failure to detect antibody 
in some patients is a technical limitation or truly due 
to alternative mechanisms of retinal injury (i.e. T-cell 
mediated). Nevertheless, we do know that seroposi-
tive patients have a worse prognosis than seronegative 
patients. Also, abnormalities in the rod and cone pho-
toreceptor function, as confirmed by electroretinogram, 
were seen three times more frequently in seropositive 
patients. Finally, central vision loss was more evident and 
more frequent in seropositive patients [25–28].
Retinal antibodies often develop prior to the clinical 
diagnosis of breast cancer. The most common of these 
antibodies are anti-enolase which was found to be the 
most prevalent antibody (32  %) in breast cancer related 
retinopathy. Anti-recoverin was found in 4.5 % of retin-
opathy patients between one and 15 years after diagno-
sis of breast cancer [29, 30]. Since the titer of anti-retinal 
antibody is correlated with disease progression, it may be 
used as a surrogate marker of disease activity [64, 66, 67]. 
Other cancer associated retinal autoantibodies have been 
described (Table  2), most of which have been shown to 
induce apoptotic death of retinal cells in vitro [68–72].
The actual titer may be more important than the mere 
presence of autoantibody when dealing with retinopathy. 
Since healthy patients sometimes are found to have very 
low titers of retinal auto-antibodies, a few studies have 
examined the impact of titer on visual manifestation and 
found a link. Most notably, a study of 178 patients with 
lung or breast cancer was reported. In the study, a high 
anti-enolase titer was most associated with late stage 
cancer and with greater damage compared to low titer 
[73–75]. In patients with high titers, ring scotomas, reti-
nal artery narrowing, and reduced response on electro-
retinogram were reported [31, 76, 77]. It is notable that 
clinical differences have been suggested with different 
auto-antibodies. For example, anti-enolase patients show 
rapidly progressive loss of vision while anti-recoverin 
patients have slowly progressive loss of vision and car-
bonic anhydrase II antibody patients tend to have color 
vision loss.
The predominant study of paraneoplastic retinopa-
thy associated with breast cancer involved 295 patients. 
Table 2 Lists the paraneoplastic retinopathy-associated antigens and their associated primary cancers
The molecular weights for target antigens are: Enolase (23 kDa), Recoverin (46 kDa), transducin β (40 kDa), carbonic anhydrase II (30 kDa) [26, 54, 64, 65]
Type of cancer The associated antigens
Breast cancer Enolase, Recoverin, Transducin β
Gynecological cancers Enolase, Aldolase C, Carbonic anhydrase II, Recoverin and GAPDH
Small cell lung cancer Recoverin
Non-small cell lung carcinoma Transducin β, Carbonic anhydrase II
Colon adenocarcinoma Transducin β, Recoverin, Carbonic anhydrase II
Bladder adenocarcinoma Enolase
Skin melanoma Enolase, Transducin β, Arrestin
Skin squamous cell carcinoma Recoverin
Cutaneous B cell lymphoma Enolase
Prostate cancer Enolase, Carbonic anhydrase II
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Serum samples from patients were examined and six 
patients were found to have high titers of retinal auto-
antibodies. On complete ophthalmologic examination, all 
of the patients had normal intraocular pressures. None 
of the patients showed any abnormalities in ophthalmo-
scopic, visual field or electroretinogram exams. All six 
had abnormal visual evoked potentials. The most fre-
quent antibody was anti-enolase followed by anti-arres-
tin. The peripheral blood lymphocytes of two of the six 
patients responded to retinal antigens, thus further sug-
gesting that T cells cooperate with antibody in causing 
retinal damage in cancer associated retinopathy [31, 32].
Paraneoplastic opsoclonus–myoclonus syndrome
Paraneoplastic opsoclonus–myoclonus syndrome (OMS) 
has been reported as one of the paraneoplastic neuro-
logical manifestations of breast cancer [33]. It is usu-
ally associated with anti-Ri antibodies that cross-react 
with two antigens, Nova-1 and Nova-2 which are widely 
expressed in the CNS. Other auto-antibodies have been 
also associated with OMS, such as anti-Yo and anti-Hu 
[78]. The syndrome is typically characterized by rapid, 
involuntary, multivectoral, conjugate fast eye movements 
(opsoclonus) and brief, involuntary twitching of muscles 
(myoclonus) with or without accompanying ataxia, apha-
sia, strabismus or mutism. Historically it is most often 
associated with neuroblastoma.
Since adult paraneoplastic OMS is rare, there are only 
small case series and a few case reports associating it with 
breast cancer. An early case series of 14 patients observed 
the syndrome in small-cell lung cancer (SCLC) (nine 
patients), non-SCLC (one patient), breast carcinoma (two 
patients), gastric adenocarcinoma (one patient) and renal 
cell carcinoma (one patient). There was frequent enceph-
alopathy in these paraneoplastic OMS patients.  Serum 
from two of the 14 paraneoplastic OMS patients con-
tained anti-neuronal antibodies and one was a patient 
with underlying breast cancer (anti-Ri in that case). The 
paraneoplastic OMS patients had steadily declining 
clinical courses despite treatment with corticosteroids 
and/or IVIG. OMS was the cause of death in five of the 
14 patients. The authors concluded that paraneoplastic 
OMS tended to occur later than idiopathic OMS and had 
a worse outcome [34, 35].
A later series of twenty-one patients from  the Mayo 
clinic with OMS were studied. In these 21 OMS patients 
(median age of 47 years), underlying cancer was detected 
in only three patients (two patients with breast cancer 
and one patient with small cell lung cancer). An infec-
tious etiology was presumed in the rest of the study 
population. Sixteen of 21 patients were given systemic 
therapy and immunotherapy. One patient received clon-
azepam alone and two received immunotherapy alone. 
Of the 19 treated patients, 13 patients had remission, 
three patients improved and the other three patients 
died. Likewise in a literature review of OMS, the cause 
of death was of neurologic complication in 60 of 116 
patients. Seven patients in that series had breast can-
cer. The most common antibody was anti-Ri seen in 15 
patients. Our literature review concludes that immuno-
therapy treatment may lead to partial or complete recov-
ery of OMS in some cases [79].
Stiff-person syndrome
Stiff-person syndrome (SPS) was previously-known as 
stiff-man syndrome and has been reported as one of the 
paraneoplastic neurological manifestations of breast can-
cer. It is an uncommon auto-immune disease that usu-
ally presents with severe muscle spasms in addition to 
thoracolumbar stiffness. It is commonly associated with 
elevated levels of glutamic acid decarboxylase (GAD) anti-
bodies, an auto-antibody often seen in diabetes mellitus 
type I. A second variant is reported and is associated with 
anti-amphiphysin antibodies [80, 81]. A SPS project from 
Yale has examined the differences in clinical presentation 
between the two types of SPS disease. Sera of 845 patients 
with any stiffness complaints were studied and a total of 
621 patients were clinically suspected of having SPS. A 
total of 116 patients had GAD antibodies and 11 patients 
had amphiphysin antibodies in association with a clinical 
stiffness syndrome. In the study, all the anti-amphiphy-
sin SPS patients were female and 10 of them had under-
lying breast cancer. Only one patient in the anti-GAD 
group had underlying breast cancer. The patients in the 
anti-amphiphysin group were older than patients in the 
anti-GAD group (mean age of 58 vs 44 years, p = 0.002). 
Patients in both groups showed stiffness, and substantial 
pain. None of the patients in the anti-amphiphysin group 
had diabetes mellitus. Eight of the 11 anti-amphiphysin 
patients had an EMG showing continuous unit activity 
of affected muscles. Regarding treatment of stiffness in 
the anti-amphiphysin group, nine patients were reported 
to have a good response to high dose benzodiazepine 
(>50 mg/day); four patients were steroid responsive; and 
three patients had a dramatic improvement after cancer 
excision/chemotherapy. Unfortunately, one patient did 
not have any response to treatment and died. The anti-
amphiphysin patients did not show any benefit from IVIG 
use [81–83]. Most of the anti-GAD patients were reported 
to have diabetes. They were also reported to be respon-
sive to high doses of benzodiazepine and to IVIG. The 
pattern of stiffness was different between the two groups. 
The anti-GAD patients showed more stiffness in the legs 
and spine than abdomen, arms, and neck. For anti-amphi-
physin patients, the pattern was equal involvement of the 
above areas (p < 0.001) [84, 85].
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The target antigen for anti-amphiphysin has been 
described as a 128-kD brain protein found at syn-
apses [86]. The amphiphysin antibodies have primarily 
been associated with invasive ductal carcinoma of the 
breast. In one report amphiphysin antibodies were not 
detected in SPS patients without underlying breast can-
cer nor were they found in the general cancer popula-
tion [87].
Treatment of SPS may include benzodiazepines and/or 
IVIG depending on the antibody type. The anti-amphi-
physin patients may also respond to plasmapheresis, ster-
oids and treatment of the primary tumor [82, 88]. Older 
reports suggests that anti-GAD patients respond to diaz-
epam, baclofen and steroids [89].
Other SPS cases in the literature include a breast can-
cer patient found to have both anti-GAD and anti-amphi-
physin antibodies. The patient was reported to improve 
here SPS symptoms after surgery and corticosteroids and 
she was reported to be stable for four years on anti-estro-
gen treatment [90]. Another patient with breast cancer 
was reported to have both OMS and SPS syndromes and 
an anti-Ri antibody. The anti-Ri antibody probably con-
tributes to GABA autoreceptor dysfunction and causes 
a glutamate–GABA imbalance contributing to muscle 
spasm/stiffness [91]. Similarly, two cases of encephalo-
myelitis and SPS in association with breast carcinoma 
have been reported and were associated with anti-amphi-
physin antibodies [92].
Another illustrative case was reported in which a 
female patient with clinical SPS was found to have a very 
high titer of anti-amphiphysin antibody (1:61,440). Based 
on the finding, she was diagnosed as having a paraneo-
plastic SPS, though no tumor could be found by routine 
mammography, CT scanning nor MRI. Eventually FDG-
PET was performed and an axillary lymph node had FDG 
uptake. The lymph node was resected and it was found to 
contain metastatic breast adenocarcinoma. The patient 
was treated with steroids and chemotherapy and had a 
dramatic neurologic response [81, 93].
A rare complication of SPS is rhabdomyolysis. There 
is one reported case of breast cancer related SPS with a 
positive anti-amphiphysin titer and complicated by rhab-
domyolysis. It is reported that SPS symptoms and rhab-
domyolysis resolved with cancer therapy [94].
The electrophysiological characteristics of SPS are 
quite interesting. Typically SPS patients have continu-
ous motor unit activity, co-contracting, and the presence 
of the cutaneo-muscular reflex. A Brazilian study of SPS 
suggested that patients with stiffness may display some or 
all of those three typical characteristics of SPS on electro-
physiological analysis [95]. Expert neurology and oncol-
ogy consultation is recommended for patients suspected 
to have SPS.
Finally, there have been a few suggestions for treat-
ment of stubbornly refractory cases of SPS. One refrac-
tory case was treated with dantrolene [96]. Clonidine and 
tizanidine have been used historically. Other clinicians 
have used intrathecal ibuprofen [97–99] or spinal cord 
stimulators [100]. Tetrahydrocannabinol and cannabidiol 
as oromucosal sprays showed some symptomatic relief 
[101].  Physical therapy interventions with ultrasound, 
soft tissue mobilizations, manual stretching, and exercise 
have also been helpful. Physical therapy for stretching, 
joint mobility and gait retraining can last for years [100].
Paraneoplastic neuropathy
One of the earliest available reports of a paraneoplastic 
sensorimotor neuropathy as a presenting symptom in 
breast cancer dates to 1994. That early report described 
nine patients with breast cancer with shared neurologi-
cal manifestations of upper and lower muscle weakness, 
muscle cramps, paresthesia, numbness and radicular 
symptoms. The patients presented with the neurological 
manifestations up to 8 years before the discovery of the 
breast cancer [59]. Seven of the nine patients had tumor 
localized to the breast and the axillary lymph nodes and 
two had stage IV disease. The neurological manifestations 
were chronic, but disability was limited. Plasmapheresis 
was used in an attempt to relieve the neurological mani-
festations of the paraneoplastic syndrome, but only one 
patient improved transiently while on plasmapheresis. 
None of the nine patients in that early study were found 
to have detectable antibodies on CSF examination. Three 
of the patients improved with anti-cancer treatment 
[102].
Other literature reports in the breast cancer field 
include a report of a single case of paraneoplastic poly-
neuropathy published in 1997. In the report, a 59  year 
old woman was admitted complaining of numbness in all 
extremities and ataxia on the left. The patient was found 
to have breast cancer and had a left mastectomy and axil-
lary lymph node resection. Sural nerve biopsy was per-
formed and serum analysis detected the presence of an 
anti-neuronal antibody [36–38].
Two additional case reports were published in 2007 
and 2014 with motor neuron dominant syndromes both 
of which improved significantly after the treatment of the 
breast cancer. One of the patients was treated with doc-
etaxel and anastrozole and the other patient was treated 
with capecitabine. Another study of seven women with 
breast cancer and motor neuron disease also found cases 
of sensorimotor neuropathy preceding the diagnosis of 
breast cancer [103].
Research into sensorimotor neuropathies related 
to cancer have observed that anti-neuronal antibod-
ies are detected in around 85 % of cases with the most 
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common antibodies being anti-Hu, anti-Yo and anti-
Ri [104, 105]. The absence of detectable antibody does 
not rule out a paraneoplastic process, as cell mediated 
nerve toxicity may act in the absence of humoral-medi-
ated effect.
The patterns of paraneoplastic neurological manifesta-
tion may vary from patient to patient. In a review of 14 
cases with paraneoplastic motor neuron disease, some 
patients had a rapidly progressive course and those were 
generally associated with anti-Hu antibodies. Other 
breast cancer patients with upper motor neuron disease 
and breast cancer had prolonged courses, no appreciable 
development of lower motor neuron signs, and no anti-
body detected in serum. The conclusion was that there 
may be wide variation in presentation and seropositivity 
in paraneoplastic neuropathy [104].
A recent retrospective study of 20 paraneoplastic 
neuropathy patients examined patterns of neuropathy 
in patients with anti-Hu antibodies. Nerve conduction 
assessments were performed and each nerve was clas-
sified as normal, demyelinating, axonal/neuronal or 
axonal/demyelinating. The study reported that, CNS 
neuropathy occurred in 40  %, autonomic neuropathy in 
30 %, and peripheral neuropathy in 95 % of the patients 
(i.e. overlap existed). The course of progression of the dis-
ease differed between patients; it was acute in one patient 
(5  %), subacute in 55  %, and progressive in the rest of 
the study population (40  %). In the patients, peripheral 
neuropathy was reported to be sensory in 70  % of the 
patients and sensorimotor in 25 %. At onset, symptoms 
were symmetrical (65 %), asymmetrical (25 %) or multi-
focal (10 %). Clinically, the main presenting symptom was 
pain in 80 % of the patients. Nerve conduction revealed 
axonal/neuronal pattern to be the most frequent (46.9 % 
of studied nerves) while axonal/demyelinating or demy-
elinating patterns were seen in 18.3 and 4.9 % of nerves, 
respectively. The axonal/neuronal pattern was more fre-
quent in sensory nerves and the mixed axonal/demyeli-
nating pattern more frequent in motor nerves (p < 0.01). 
In patients with a clinically apparent sensory neuropathy, 
88.5 % of sensory nerves were abnormal, mostly with an 
axonal/neuronal pattern. In patients with a sensorimo-
tor neuropathy, 96.6  % of sensory nerves and 71  % of 
motor nerves were abnormal. The study concluded that 
pure sensory neuropathy is not a common paraneoplastic 
finding, while motor neuropathy may be a more frequent 
paraneoplastic effect [106].
There are no randomized controlled trials of treatment 
for paraneoplastic neuropathy to use for practice guid-
ance. The evidence from case series, case reports and a 
few expert opinions would suggest that immunomodula-
tion with IVIG, plasmapheresis, steroids or chemother-
apy are likely to be useful.
Paraneoplastic encephalomyelitis
Paraneoplastic encephalomyelitis is another rare para-
neoplastic neurological manifestation of breast cancer. It 
may involve different areas of the CNS such as the hip-
pocampus, the lower brain stem, spinal root ganglia or 
dorsal root ganglia [6, 38]. Due to involvement of variable 
areas of the nervous system, the clinical picture usually 
has a wide range of neurological manifestations. It can 
lead to limbic encephalitis (LE), brain stem syndromes, 
autonomic dysfunction, myelitis, chronic gastrointestinal 
pseudo-obstruction (CGP), cerebellar ataxia and sensory 
polyneuropathy (SSN). Limbic encephalitis, SSN and 
cerebellar ataxia are the most common clinical presen-
tations and autonomic neuropathy is present in around 
30 % of the patients [38, 107].
Specifically, LE is the most common form of paraneo-
plastic encephalomyelitis. It may present with an acute 
or sub-acute onset of symptoms such as confusion, loss 
of short term memory or seizures. In most reports, small 
cell lung cancer makes up the majority of cases of para-
neoplastic LE, followed by testicular tumors in around 
20 % of cases and then by breast cancer in 8 % of cases [5, 
108, 109]. There are case reports of paraneoplastic limbic 
encephalitis involving the extra-limbic structures leading 
to overlap syndromes [110]. The diagnosis is most often 
made based on characteristic findings on a brain MRI. 
The findings of hyperintensity signals on T2-weighted 
or fluid attenuation inversion recovery (FLAIR) images 
involving one or both medial temporal lobes, when pre-
sent, are specific for LE but they are not found in every 
patient [7]. The formal diagnosis of limbic encephali-
tis may be challenging. In one case series, there were 50 
patients fulfilling criteria to be diagnosed with paraneo-
plastic limbic encephalitis, yet only 30 patients had anti-
neuronal antibodies (18 anti-Hu, 10 anti-Ta, 2 anti-Ma) 
while 20 patients were anti-neuronal antibody negative. 
Half of the patients had signal abnormalities in the limbic 
system on MRI [7].
A well characterized example is reported for a patient 
with medullary breast cancer and paraneoplastic lim-
bic encephalitis. The patient presented with clinical 
manifestations of limbic/brain stem encephalitis and 
anti-Ma2 antibodies in her serum and CSF (confirmed 
with western blot). The patient presented with multiple 
neurological signs that fit with the diagnosis of enceph-
alitis. Both T2 weighted and FLAIR images on MRI 
showed areas of high signal strength in the bilateral 
mesial temporal lobes, the amygdala, the hippocampus, 
and the hypothalamus. There was no region of mass 
effect or gadolinium enhancement. The cerebral cortex 
and brain stem were not affected. A chest CT showed 
swelling of an axillary lymph node. A mammogram 
was ordered and showed a mass in the right breast that 
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was not palpable. A needle biopsy was performed and 
medullary breast cancer was diagnosed. The cancer was 
excised but the neurological manifestations persisted 
and showed further deterioration. Intravenous meth-
ylprednisolone followed by oral prednisone were used 
and modest cognitive improvement was achieved, but 
the radiographic changes on the MRI were not revers-
ible [39–44].
In regard to diagnosis, a study at Mayo clinic of LE 
patients used EEG and found focal or generalized slow-
ing and/or epileptiform activity, maximal in the tem-
poral regions, in all 22 patients assessed. MRI revealed 
increased T2 signal involving one or both temporal lobes 
in 15 of 18 patients. CSF results were abnormal in 18 of 
23 patients tested. Clinical or radiographic evidence of 
extra-limbic involvement was documented in 12 of 22 
patients [111].
Regarding treatment and follow up, the treatment of 
the tumor appeared to have a greater effect on the neuro-
logical outcome than did the use of immunosuppression. 
Improvement was observed in 38  % of anti-Hu patients, 
30  % of anti-Ta patients and 64  % of patients without 
these antibodies [7]. In a series of 71 patients with para-
neoplastic encephalomyelitis or sensory neuronopathy, 
treatment using steroids and plasmapharesis did not 
show improvement in any of the patients. In the studied 
patients, the most common cause of death was autonomic 
and respiratory failure, which was either of central origin 
or due to muscle weakness [112]. In a separate case series, 
with 14 % breast cancer patients, the only treatment that 
showed improvement or stabilization of the clinical con-
dition was anti-tumor treatment [113]. Furthermore, a 
study examined the role of IVIG in 22 patients with para-
neoplastic encephalomyelitis and sensory neuropathy syn-
dromes. Ten patients in the study remained stable (eight 
patients with anti-Hu and two with anti-Yo antibodies), 
ten patients deteriorated and one patient had an initial 
stabilization response that worsened when the IVIG was 
stopped. No change in serum antibody titers was noticed 
with treatment with IVIG. The final study conclusion was 
that, IVIG use had little clinical benefit in patients with 
paraneoplastic encephalomyelitis [114].
Ultimately, controlling paraneoplastic encephalomy-
elitis is a challenging clinical problem. The patients are 
reported to have a poor quality of life and limited treat-
ments as above. Therefore, symptom control is often 
the mainstay of therapy. Symptomatic treatment can 
include medications for seizure control and for auto-
nomic symptom improvement. Also physiotherapy plays 
an important role in addition to occupational, speech and 
psychological therapies.
Conclusion
Patients with neurologic manifestations that are unex-
plained by any other neurological disorder should be 
tested for antineural antibodies. Although the sensitiv-
ity and specificity of these antibodies are not 100 %, they 
can aide in the diagnosis. Likewise, their absence does 
not exclude the diagnosis of paraneoplastic syndromes 
as T cell mediated paraneoplastic syndromes are well 
reported. The immune mechanisms underlying these 
syndromes are partially explained by IFN-α and IL-12 
production along with marrow resident B cell activa-
tion. It has been speculated that the impending addition 
of checkpoint inhibitors to the breast cancer armamen-
tarium might increase the frequency of paraneoplastic 
syndromes in breast cancer, but the limited data to date 
has not demonstrated an increase in these syndromes. 
Nevertheless, investigators are urged to remain vigilant 
as this class of drugs is developed.
Owing to the rarity of these syndromes, few prospec-
tive studies are available and existing data is mostly based 
on observations. Treatment is often empiric and should 
be tailored for each case. In paraneoplastic neurologic 
syndromes, treatment of the underlying tumor is of vital 
importance. Secondarily, immunosuppressive therapy 
may be helpful in some cases (see Table  3). A moder-
ate degree of therapy with steroids and/or IVIG, and/or 
plasma exchange may prove helpful, especially in OMS 
and paraneoplastic neuropathy. If more aggressive immu-
nosuppression is deemed necessary, then cyclophospha-
mide, mycophenolate or rituximab may be considered. 
Immunosuppressive therapy should not be delayed as the 
sooner the treatment, the better the outcome. Evaluation 
for presence of auto-antibodies and cancer diagnosis may 
take some time, so treatment should be started based on 
clinical suspicion and after exclusion of infections and 
other causes [110, 115–117].
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